News
The FDA has granted marketing authorization to CT-132 for the preventive treatment of episodic migraine in patients aged 18 years and older.
The FDA has granted marketing authorization to CT-132, an adjunctive, prescription digital therapeutic for the preventive treatment of episodic migraine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback